Mary Tomayko is a Dermatology physician affiliated with Yale University. OpenAlex indexes 71 publications with 5,429 citations (h-index 23). By OpenAlex citation count, this profile ranks in the top 10% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
4 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
23.3%Interleukin-4 Receptor alpha Antagonist16.4%Dupixent Syringe70%Dupixent Pen31%Part D<11 patientsCorticosteroid6.9%Triamcinolone Acetonide100%Part D≥37 patientsCancer & immunology
20.7%Folate Analog Metabolic Inhibitor10.1%Methotrexate100%Part D≥19 patientsCalcineurin inhibitor3.6%Tacrolimus100%Part D≥15 patients+ 3 more classes in this area
Metabolism & gastrointestinal
19%Corticosteroid16.5%Prednisone100%Part D≥24 patientsProton pump inhibitor2.5%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2008–2025 per NIH RePORTER. The latest:
- B Cell Memory Regulation by Bone Morphogenetic Protein Receptor 1A
Yale University
FY2019$414,642R01AI122448 - B Cell Memory Regulation by Bone Morphogenetic Protein Receptor 1A
Yale University
FY2018$424,493R01AI122448
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”